Efflux-mediated multiresistance in Gram-negative bacteria

Clinical Microbiology and Infection

Volumn 10, Issue 1, 2004, Pages 12-26

  Poole, K ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Efflux; Gram negative; Multidrug; Multiresistance; Resistance

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BIOCIDE; CARBENICILLIN; CEFOTAXIME; CHLORAMPHENICOL; CIPROFLOXACIN; DOXORUBICIN; GENTAMICIN; LINEZOLID; MACROLIDE; METHOTREXATE; MINOCYCLINE; MULTIDRUG RESISTANCE PROTEIN; NALIDIXIC ACID; NORFLOXACIN; NOVOBIOCIN; PENICILLIN G; PUROMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE; THIOLACTOMYCIN; TIGECYCLINE; UNINDEXED DRUG;

ACINETOBACTER; ANTIBIOTIC THERAPY; ENTEROBACTERIACEAE; GENE SEQUENCE; GENOME ANALYSIS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STENOTROPHOMONAS MALTOPHILIA; SUBSPECIES; UNINDEXED SEQUENCE;

ACINETOBACTER; BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 1642422948     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00763.x     Document Type: Review

References (149)

1. Waterer GW, Wunderink RG. Increasing threat of Gram-negative bacteria. Crit Care Med 2001; 29: N75-N81.
2. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 2001; 119: 397S-404S.
3. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis 2003; 36: S11-S23.
4. Poole K. Overcoming multidrug resistance in Gram-negative bacteria. Curr Opin Invest Drugs 2003; 4: 128-139.
5. Hosein IK, Hill DW, Jenkins LE, Magee JT. Clinical significance of the emergence of bacterial resistance in the hospital environment. J Appl Microbiol 2002; 92(suppl 1): 90S-97S.
6. Helms M, Vastrup P, Gerner-Smidt P, Molbak K. Excess mortality associated with antimicrobial drug-resistant Salmonella typhimurium. Emerg Infect Dis 2002; 8: 490-495.
7. Carmeli Y, Troillet N, Karchmer AW, Samore MH. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999; 159: 1127-1132.
8. Niederman MS. Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit Care Med 2001; 29: N114-N120.
9. Poole K. Mechanisms of bacterial biocide and antibiotic resistance. J Appl Microbiol 2002; 92(suppl 1): 55S-64S.
10. Hogan D, Kolter R. Why are bacteria refractory to antimicrobials? Curr Opin Microbiol 2002; 5: 472-477.
11. Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med 2002; 252: 91-106.
12. Rowe-Magnus DA, Davies J, Mazel D. Impact of integrons and transposons on the evolution of resistance and virulence. Curr Top Microbiol Immunol 2002; 264: 167-188.
13. Poole K. Outer membranes and efflux: the path to multidrug resistance in gram-negative bacteria. Curr Pharm Biotechnol 2002; 3: 77-98.
14. Poole K. Multidrug resistance in Gram-negative bacteria. Curr Opin Microbiol 2001; 4: 500-508.
15. Webber MA, Piddock LJ. The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 2003; 51: 9-11.
16. Paulsen IT, Chen J, Nelson KE, Saier MH. Comparative genomics of microbial drug efflux systems. J Mol Microbiol Biotechnol 2001; 3: 145-150.
17. Putman M, van Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. Microbiol Mol Biol Rev 2000; 64: 672-693.
18. Zgurskaya HI, Nikaido H. Multidrug resistance mechanisms: drug efflux across two membranes. Mol Microbiol 2000; 37: 219-225.
19. Kobayashi N, Nishino K, Yamaguchi A. Novel macrolide-specific ABC-type efflux transporter in Escherichia coli. J Bacteriol 2001; 183: 5639-5644.
20. Poole K. Efflux-mediated resistance to fluoroquinolones in Gram-negative bacteria. Antimicrob Agents Chemother 2000; 44: 2233-2241.
21. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001; 3: 255-264.
22. Sanchez P, Linares JF, Ruiz-Diez B et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J Antimicrob Chemother 2002; 50: 657-664.
23. Cosson P, Zulianello L, Join-Lambert O et al. Pseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host system. J Bacteriol 2002; 184: 3027-3033.
24. Hirakata Y, Srikumar R, Poole K et al. Multidrug efflux systems play an important role in the invasiveness of Pseudomonas aeruginosa. J Exp Med 2002; 196: 109-118.
25. Baranwal S, Dey K, Ramamurthy T, Nair GB, Kundu M. Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of Vibrio cholerae. Antimicrob Agents Chemother 2002; 46: 2676-2678.
26. Navia MM, Ruiz J, Ribera A, de Anta MT, Vila J. Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii. J Antimicrob Chemother 1999; 44: 743-748.
27. Ishii H, Sato K, Hoshino K et al. Active efflux of ofloxacin by a highly quinolone-resistant strain of Proteus vulgaris. J Antimicrob Chemother 1991; 28: 827-836.
28. Nikaido H, Zgurskaya HI. AcrAB and related multidrug efflux pumps of Escherichia coli. J Mol Microbiol Biotechnol 2001; 3: 215-218.
29. Shafer WM, Veal WL, Lee EH, Zarantonelli L, Balthazar JT, Rouquette C. Genetic organization and regulation of antimicrobial efflux systems possessed by Neisseria gonorrhoeae and Neisseria meningitidis. J Mol Microbiol Biotechnol 2001; 3: 219-224.
30. Mazzariol A, Tokue Y, Kanegawa TM, Cornaglia G, Nikaido H. High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA. Antimicrob Agents Chemother 2000; 44: 3441-3443.
31. Linde HJ, Notka F, Metz M, Kochanowski B, Heisig P, Lehn N. In vivo increase in resistance to ciprofloxacin in Escherichia coli associated with deletion of the C-terminal part of MarR. Antimicrob Agents Chemother 2000; 44: 1865-1868.
32. Pradel E, Pages JM. The AcrAB-TolC efflux pump contributes to multidrug resistance in the nosocomial pathogen Enterobacter aerogenes. Antimicrob Agents Chemother 2002; 46: 2640-2643.
33. Gayet S, Chollet R, Molle G, Pages JM, Chevalier J. Modification of outer membrane protein profile and evidence suggesting an active drug pump in Enterobacter aerogenes clinical strains. Antimicrob Agents Chemother 2003; 47: 1555-1559.
34. Linde HJ, Notka F, Irtenkauf C et al. Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae. J Antimicrob Chemother 2002; 49: 625-630.
35. Mazzariol A, Zuliani J, Cornaglia G, Rossolini GM, Fontana R. AcrAB efflux system: expression and contribution to fluoroquinolone resistance in Klebsiella spp. Antimicrob Agents Chemother 2002: 46: 3984-3986.
36. Zarantonelli L, Borthagaray G, Lee EH, Veal W, Shafer WM. Decreased susceptibility to azithromycin and erythromycin mediated by a novel mtr (R) promoter mutation in Neisseria gonorrhoeae. J Antimicrob Chemother 2001; 47: 651-654.
37. Veal WL, Nicholas RA, Shafer WM. Overexpression of the MtrC-MtrD-MtrE efflux pump due to an mtrR mutation is required for chromosomally mediated penicillin resistance in Neisseria gonorrhoeae. J Bacteriol 2002; 184: 5619-5624.
38. Cousin JS, Whittington WL, Roberts MC. Acquired macrolide resistance genes and the 1 bp deletion in the mtrR promoter in Neisseria gonorrhoeae. J Antimicrob Chemother 2003; 51: 131-133.
39. Randall LP, Cooles SW, Sayers AR, Woodward MJ. Association between cyclohexane resistance in Salmonella of different serovars and increased resistance to multiple antibiotics, disinfectants and dyes. J Med Microbiol 2001; 50: 919-924.
40. Baucheron S, Imberechts H, Chaslus-Dancla E, Cloeckaert A. The AcrB multidrug transporter plays a major role in high-level fluoroquinolone resistance in Salmonella enterica serovar typhimurium phage type DT204. Microb Drug Resist 2002; 8: 281-289.
41. Piddock LJ. Fluoroquinolone resistance in Salmonella serovars isolated from humans and food animals. FEMS Microbiol Rev 2002; 26: 3-16.
42. Piddock LJ, White DG, Gensberg K, Pumbwe L, Griggs DJ. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 2000; 44: 3118-3121.
43. Soto SM, Ruiz J, Mendoza MC, Vila J. In vitro fluoroquinolone-resistant mutants of Salmonella enterica serotype Enteritidis: analysis of mechanisms involved in resistance. Int J Antimicrob Agents 2003; 22: 537-540.
44. Jalal S, Ciofu O, Hoiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis. Antimicrob Agents Chemother 2000; 44: 710-712.
45. Cavallo JD, Plesiat P, Couetdic G, Leblanc F, Fabre R. Mechanisms of β-lactam resistance in Pseudomonas aeruginosa: prevalence of OprM-overproducing strains in a French multicentre study (1997). J Antimicrob Chemother 2002; 50: 1039-1043.
46. Higgins PG, Fluit AC, Milatovic D, Verhoef J, Schmitz FJ. Mutations in GyrA, ParC, MexR and NfxB in clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents 2003; 21: 409-413.
47. Sobel ML, McKay GA, Poole K. Contribution of the MexXY multidrug transporter to aminoglycoside resistance in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2003; 47: 3202-3207.
48. Zhang L, Li X-Z, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 2000; 44: 287-293.
49. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell division-type efflux pump involved in amino-glycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45: 3375-3380.
50. Burns JL, Hedin LA, Lien DM. Chloramphenicol resistance in Pseudomonas cepacia because of decreased permeability. Antimicrob Agents Chemother 1989; 33: 136-141.
51. Kumar A, Worobec EA. Fluoroquinolone resistance of Serratia marcescens: involvement of a proton gradient-dependent efflux pump. J Antimicrob Chemother 2002; 50: 593-596.
52. Luo N, Sahin O, Lin J, Michel LO, Zhang Q. In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump. Antimicrob Agents Chemother 2003; 47: 390-394.
53. Mallea M, Chevalier J, Bornet C et al. Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes. Microbiology 1998; 144: 3003-3009.
54. Deguchi T, Kawamura T, Yasuda M et al. In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections. Antimicrob Agents Chemother 1997; 41: 1609-1611.
55. Martínez-Martínez L, García I, Ballesta S, Benedí VJ, Hernández-Allés S, Pascual A. Energy-dependent accumulation of fluoroquinolones in quinolone-resistant Klebsiella pneumoniae strains. Antimicrob Agents Chemother 1998; 42: 1850-1852.
56. McMurry LM, Oethinger M, Levy SB. Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli. FEMS Microbiol Lett 1998; 166: 305-309.
57. Moken MC, McMurry LM, Levy SB. Selection of multiple-antibiotic-resistant (Mar) mutants of Escherichia coli by using the disinfectant pine oil: roles of the mar and acrAB loci. Antimicrob Agents Chemother 1997; 41: 2770-2772.
58. Nishino K, Yamaguchi A. Analysis of a complete library of putative drug transporter genes in Escherichia coli. J Bacteriol 2001; 183: 5803-5812.
59. Schweizer HP. Intrinsic resistance to inhibitors of fatty acid biosynthesis in Pseudomonas aeruginosa is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems. Antimicrob Agents Chemother 1998; 42: 394-398.
60. Chuanchuen R, Beinlich K, Hoang TT, Becher A, Karkhoff-Schweizer RR, Schweizer HP. Cross-resistance between triclosan and antibiotics in Pseudomonas aeruginosa is mediated by multidrug efflux pumps: exposure of a susceptible mutant strain to triclosan selects nfxB mutants overexpressing MexCD-OprJ. Antimicrob Agents Chemother 2001; 45: 428-432.
61. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol 2002; 184: 5036-5044.
62. McBain AJ, Rickard AH, Gilbert P. Possible implications of biocide accumulation in the environment on the prevalence of bacterial antibiotic resistance. J Ind Microbiol Biotechnol 2002; 29: 326-330.
63. Fraise AP. Reply. J Antimicrob Chemother 2002; 50: 139-140.
64. Gilbert P, McBain AJ, Bloomfield SF. Biocide abuse and antimicrobial resistance: being clear about the issues. J Antimicrob Chemother 2002; 50: 137-139.
65. Fraise AP. Biocide abuse and antimicrobial resistance - a cause for concern? J Antimicrob Chemother 2002; 49: 11-12.
66. Schweizer HP. Triclosan: a widely used biocide and its link to antibiotics. FEMS Microbiol Lett 2001; 202: 1-7.
67. Ng ME, Jones S, Leong SH, Russell AD. Biocides and antibiotics with apparently similar actions on bacteria: is there the potential for cross-resistance? J Hosp Infect 2002; 51: 147-149.
68. Russell AD. Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria. J Appl Microbiol 2002; 92(suppl 1): 121S-135S.
69. Gilbert P, McBain AJ. Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. Clin Microbiol Rev 2003; 16: 189-208.
70. Russell AD. Biocides and pharmacologically active drugs as residues and in the environment: is there a correlation with antibiotic resistance? Am J Infect Control 2002; 30: 495-498.
71. Li X-Z, Zhang L, Poole K. Interplay between the MexAB-OprM multidrug efflux system and the outer membrane barrier in the multiple antibiotic resistance of Pseudomonas aeruginosa. J Antimicrob Chemother 2000; 45: 433-436.
72. Randall LP, Woodward MJ. The multiple antibiotic resistance (mar) locus and its significance. Res Vet Sci 2002; 72: 87-93.
73. Cohen SH, Yan W, Levy SB. A multidrug resistance regulatory chromosomal locus is widespread among enteric bacteria. J Infect Dis 1993; 168: 484-488.
74. Chollet R, Bollet C, Chevalier J, Mallea M, Pages JM, Davin-Regli A. mar operon involved in multidrug resistance of Enterobacter aerogenes. Antimicrob Agents Chemother 2002; 46: 1093-1097.
75. Nakajima A, Sugimoto Y, Yoneyama H, Nakae T. High-level fluoroquinolone resistance in Pseudomonas aeruginosa due to interplay of the MexAB-OprM efflux pump and the DNA gyrase mutation. Microbiol Immunol 2002; 46: 391-395.
76. Tavio M, Vila J, Ruiz J et al. In vitro selected fluoroquinolone-resistant mutants of Citrobacter freundii: analysis of the quinolone resistance acquisition. J Antimicrob Chemother 2000; 45: 521-524.
77. Le TI, Couetdic G, Clermont O, Brahimi N, Plesiat P, Bingen E. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. J Antimicrob Chemother 2001; 48: 553-555.
78. Martinez-Martinez L, Pascual A, Conejo MC et al. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum β-lactamase production. Antimicrob Agents Chemother 2002; 46: 3926-3932.
79. Oethinger M, Kern WV, Jellen-Ritter AS, McMurry LM, Levy SB. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother 2000; 44: 10-13.
80. Lomovskaya O, Lee A, Hoshino K et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1340-1346.
81. Poole K. Overcoming antimicrobial resistance by targeting resistance mechanisms. J Pharm Pharmacol 2001; 53: 283-294.
82. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J Mol Microbiol Biotechnol 2001; 3: 225-236.
83. Dean CR, Visalli MA, Projan SJ, Sum P-E, Bradford PA. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003; 47: 972-978.
84. Betriu C, Rodriguez-Avial I, Sanchez BA, Gomez M, Alvarez J, Picazo JJ. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002; 46: 892-895.
85. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003; 47: 665-669.
86. Tegos G, Stermitz FR, Lomovskaya O, Lewis K. multidrug pump inhibitors uncover remarkable activity of plant antimicrobials. Antimicrob Agents Chemother 2002; 46: 3133-3141.
87. Ali ST, Gill AE, Lewendon A. Novel targets for antibiotic drug design. Curr Opin Invest Drugs 2002; 3: 1712-1717.
88. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 2242-2246.
89. Morita Y, Komori Y, Mima T, Kuroda T, Mizushima T, Tsuchiya T. Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from Pseudomonas aeruginosa PAO1: MexCD-OprJ is an inducible pump. FEMS Microbiol Lett 2001; 202: 139-143.
90. Morita Y, Murata T, Mima T et al. Induction of mexCD-oprJ operon for a multidrug efflux pump by disinfectants in wild-type Pseudomonas aeruginosa PAO1. J Antimicrob Chemother 2003; 5: 991-994.
91. Ma D, Cook DN, Alberti M, Pon NG, Nikaido H, Hearst JE. Genes acrA and acrB encode a stress-induced system of Escherichia coli. Mol Microbiol 1995; 16: 45-55.
92. Thanassi DG, Cheng LW, Nikaido H. Active efflux of bile salts in Escherichia coli. J Bacteriol 1997; 179: 2512-2518.
93. Shafer WM, Balthazar JT, Hagman KE, Morse SA. Missense mutations that alter the DNA-binding domain of the MtrR protein occur frequently in rectal isolates of Nesseria gonorrhoeae that are resistant to fecal lipids. Microbiology 1995; 141: 907-911.
94. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995; 141: 611-622.
95. Poole K. Bacterial multidrug resistance - emphasis on efflux mechanisms and Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 34: 453-456.
96. Helling RB, Janes BK, Kimball H et al. Toxic waste disposal in Escherichia coli. J Bacteriol 2002; 184: 3699-3703.
97. Palumbo JD, Kado CI, Phillips DA. An isoflavonoid-inducible efflux pump in Agrobacterium tumefaciens is involved in competitive colonization of roots. J Bacteriol 1998; 180: 3107-3113.
98. Ryan BM, Dougherty TJ, Beaulieu D, Chuang J, Dougherty BA, Barrett JF. Efflux in bacteria: what do we really know about it? Expert Opin Invest Drugs 2001; 10: 1409-1422.
99. Miller LA, Ratnam K, Payne DJ. β-Lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001; 1: 451-458.
100. Koronakis V, Sharff A, Koronakis E, Luisi B, Hughes C. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 2000; 405: 914-919.
101. Murakami S, Nakashima R, Yamashita E, Yamaguchi A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 2002; 419: 587-593.
102. Avila-Sakar AJ, Misaghi S, Wilson-Kubalek EM et al. Lipid-layer crystallization and preliminary three-dimensional structural analysis of AcrA, the periplasmic component of a bacterial multidrug efflux pump. J Struct Biol 2001; 136: 81-88.
103. Mao W, Warren MS, Black DS et al. On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition. Mol Microbiol 2002; 46: 889-901.
104. Tikhonova EB, Wang Q, Zgurskaya HI. Chimeric analysis of the multicomponent multidrug efflux transporters from Gram-negative bacteria. J Bacteriol 2002; 184: 6499-6507.
105. Elkins CA, Nikaido H. Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of Escherichia coli is determined predominately by two large periplasmic loops. J Bacteriol 2002; 184: 6490-6498.
106. Eda S, Maseda H, Nakae T. An elegant means of self-protection in Gram-negative bacteria by recognizing and extruding xenobiotics from the periplasmic space. J Biol Chem 2003; 278: 2085-2088.
107. Yu EW, McDermott G, Zgurskaya HI, Nikaido H, Koshland DE. Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science 2003; 300: 976-980.
108. Peng WT, Nester EW. Characterization of a putative RND-type efflux system in Agrobacterium tumefaciens. Gene 2001; 270: 245-252.
109. Pumbwe L, Piddock LJ. Identification and molecular characterisation of CmeB, a Campylobacter jejuni multidrug efflux pump. FEMS Microbiol Lett 2002; 206: 185-189.
110. Lin J, Michel LO, Zhang Q. CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrob Agents Chemother 2002; 46: 2124-2131.
111. Nagakubo S, Nishino K, Hirata T, Yamaguchi A. The putative response regulator BaeR stimulates multidrug resistance of Escherichia coli via a novel multidrug exporter system, MdtABC. J Bacteriol 2002; 184: 4161-4167.
112. Baranova N, Nikaido H. The BaeSR two-component regulatory system activates transcription of the yegM-NOB (mdtABCD) transporter gene cluster in Escherichia coli and increases its resistance to novobiocin and deoxycholate. J Bacteriol 2002; 184: 4168-4176.
113. Masuda N, Church GM. Escherichia coli gene expression responsive to levels of the response regulator EvgA. J Bacteriol 2002; 184: 6225-6234.
114. Nishino K, Yamaguchi A. EvgA of the two-component signal transduction system modulates production of the YhiUV multidrug transporter in Escherichia coli. J Bacteriol 2002; 184: 2319-2323.
115. Sulavik MC, Houseweart C, Cramer C et al. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother 2001; 45: 1126-1136.
116. Ikeda T, Yoshimura F. A resistance-nodulation-cell division family xenobiotic efflux pump in an obligate anaerobe, Porphyromonas gingivalis. Antimicrob Agents Chemother 2002; 46: 3257-3260.
117. Aendekerk S, Ghysels B, Cornelis P, Baysse C. Characterization of a new efflux pump, MexGHI-OpmD, from Pseudomonas aeruginosa that confers resistance to vanadium. Microbiology 2002; 148: 2371-2381.
118. Sekiya H, Mima T, Morita Y, Kuroda T, Mizushima T, Tsuchiya T. Functional cloning and characterization of a multidrug efflux pump, MexHI-OpmD, from a Pseudomonas aeruginosa mutant. Antimicrob Agents Chemother 2003; 47: 2990-2992.
119. Li Y, Mima T, Komori Y et al. A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa. J Antimicrob Chemother 2003; 52: 572-575.
120. Berlanga M, Vazquez JL, Hernandez-Borrell J, Montero MT, Vinas M. Evidence of an efflux pump in Serratia marcescens. Microb Drug Resist 2000; 6: 111-117.
121. Chen J, Kuroda T, Huda MN, Mizushima T, Tsuchiya T. An RND-type multidrug efflux pump SdeXY from Serratia marcescens. J Antimicrob Chemother 2003; 52: 176-179.
122. Rahmati S, Yang S, Davidson AL, Zechiedrich EL. Control of the AcrAB multidrug efflux pump by quorum-sensing regulator SdiA. Mol Microbiol 2002; 43: 677-685.
123. Wei Y, Lee JM, Smulski DR, LaRossa RA. Global impact of sdiA amplification revealed by comprehensive gene expression profiling of Escherichia coli. J Bacteriol 2001; 183: 2265-2272.
124. Tsukagoshi N, Aono R. Entry into and release of solvents by Escherichia coli in an organic-aqueous two-liquid-phase system and substrate specificity of the AcrAB-TolC solvent-extruding pump. J Bacteriol 2000; 182: 4803-4810.
125. Kopytek SJ, Dyer JC, Knapp GS, Hu JC. Resistance to methotrexate due to AcrAB-dependent export from Escherichia coli. Antimicrob Agents Chemother 2000; 44: 3210-3212.
126. Jellen-Ritter AS, Kern WV. Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in Escherichia coli mutants selected with a fluoroquinolone. Antimicrob Agents Chemother 2001; 45: 1467-1472.
127. O'Neill AJ, Bostock JM, Morais MA, Chopra I. Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. J Antimicrob Chemother 2002; 50: 839-848.
128. Kobayashi K, Tsukagoshi N, Aono R. Suppression of hypersensitivity of Escherichia coli acrB mutant to organic solvents by integration activation of the aceEF operon with the IS 1 or IS2 element. J Bacteriol 2001; 183: 2646-2453.
129. Veal WL, Shafer WM. Identification of a cell envelope protein (MtrF) involved in hydrophobic antimicrobial resistance in Neisseria gonorrhoeae. J Antimicrob Chemother 2003; 51: 27-37.
130. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44: 3322-3327.
131. Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. J Infect Chemother 2002; 8: 371-373.
132. Okamoto K, Gotoh N, Nishino T. Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46: 2696-2699.
133. Koutsolioutsou A, Martins EA, White DG, Levy SB, Demple B. A soxRS-constitutive mutation contributing to antibiotic resistance in a clinical isolate of Salmonella enterica (serovar typhimurium). Antimicrob Agents Chemother 2001; 45: 38-43.
134. Giraud E, Cloeckaert A, Kerboeuf D, Chaslus-Dancla E. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother 2000; 44: 1223-1228.
135. Shyu JB, Lies DP, Newman DK. Protective role of tolC in efflux of the electron shuttle anthraquinone-2,6-disulfonate. J Bacteriol 2002; 184: 1806-1810.
136. Sanchez P, Alonso A, Martinez JL. Cloning and characterization of SmeT, a repressor of the Stenotrophomonas maltophilia multidrug efflux pump SmeDEF. Antimicrob Agents Chemother 2002; 46: 3386-3393.
137. Zhang L, Li X-Z, Poole K. The SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 2001; 45: 3497-3503.
138. Teran W, Felipe A, Segura A, Rojas A, Ramos JL, Gallegos M-T. Antibiotic-dependent induction of Pseudomonas putida DOT-T1E TtgABC efflux pump is mediated by the drug binding repressor TtgR. Antimicrob Agents Chemother 2003; 47: 3067-3072.
139. Rojas A, Segura A, Guazzaroni ME et al. In vivo and in vitro evidence that TtgV is the specific regulator of the TtgGHI multidrug and solvent efflux pump of Pseudomonas putida. J Bacteriol 2003; 185: 4755-4763.
140. Hirakawa H, Nishino K, Hirata T, Yamaguchi A. Comprehensive studies of drug resistance mediated by overexpression of response regulators of two-component signal transduction systems in Escherichia coli. J Bacteriol 2003; 185: 1851-1856.
141. Nishino K, Yamada J, Hirakawa H, Hirata T, Yamaguchi A. Roles of TolC-dependent multidrug transporters of Escherichia coli in resistance to β-lactams. Antimicrob Agents Chemother 2003; 47: 3030-3033.
142. Miyamae S, Ueda O, Yoshimura F, Hwang J, Tanaka Y, Nikaido H. A MATE family multidrug efflux transporter pumps out fluoroquinolones in Bacteroides thetaiotaomicron. Antimicrob Agents Chemother 2001; 45: 3341-3346.
143. Ninio S, Rotem D, Schuldiner S. Functional analysis of novel multidrug transporters from human pathogens. J Biol Chem 2001; 276: 48250-48256.
144. Braibant M, Guilloteau L, Zygmunt MS. Functional characterization of Brucella melitensis NorMI, an efflux pump belonging to the multidrug and toxic compound extrusion family. Antimicrob Agents Chemother 2002; 46: 3050-3053.
145. Wigfield SM, Rigg GP, Kavari M, Webb AK, Matthews RC, Burnie JP. Identification of an immunodominant drug efflux pump in Burkholderia cepacia. J Antimicrob Chemother 2002; 49: 619-624.
146. Fehlner-Gardiner CC, Valvano MA. Cloning and characterization of the Burkholderia vietnamiensis norM gene encoding a multi-drug efflux protein. FEMS Microbiol Lett 2002; 215: 279-283.
147. Rouquette-Loughlin C, Dunham SA, Kuhn M, Balthazar JT, Shafer WM. The NorM efflux pump of Neisseria gonorrhoeae and Neisseria meningitidis recognizes antimicrobial cationic compounds. J Bacteriol 2003; 185: 1101-1106.
148. Li X-Z, Poole K, Nikaido H. Contributions of MexAB-OprM and an EmrE homologue to intrinsic resistance of Pseudomonas aeruginosa to aminoglycosides and dyes. Antimicrob Agents Chemother 2003; 47: 27-33.
149. Chen J, Morita Y, Huda MN, Kuroda T, Mizushima T, Tsuchiya T. VmrA, a member of a novel class of Na (+)-coupled multidrug efflux pumps from Vibrio parahaemolyticus. J Bacteriol 2002; 184: 572-576.